Sigyn Therapeutics reported net income of -$0.58M for the quarter ended Sep 2025. This income statement covers 37 quarters of results from Mar 2016 through Sep 2025, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2016 | Dec2016 | Mar2017 | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||||||||||||||||
| Cost of RevenueCost of Rev | 200.00 | 0.08M | 0.08M | 250.00 | 131.00 | 65.00 | 11.00 | 184.00 | 100.00 | 51.00 | 57.00 | 338.00 | 8.00 | 114.00 | 670.00 | 176.00 | 8.00 | 52.00 | |||||||||||||||||||
| Gross Profit | |||||||||||||||||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 0.42M | 0.12M | 0.14M | 0.23M | 0.25M | 0.23M | 0.15M | 0.13M | 0.14M | 0.15M | 0.22M | 0.22M | 0.22M | 0.23M | 0.24M | 0.21M | 0.09M | 0.01M | 0.01M | 0.03M | |||||||||||||||||
| Selling, General & AdministrativeSG&A | -0.07M | 0.20M | 0.22M | 0.35M | 0.51M | 0.38M | 0.38M | 0.40M | 0.33M | 0.34M | 0.32M | 0.39M | 0.61M | 0.36M | 0.32M | 0.56M | 0.50M | 0.49M | 0.41M | 0.31M | |||||||||||||||||
| Other Operating ExpensesOther Opex | 200.00 | 0.08M | 0.08M | -0.16M | 250.00 | 131.00 | 65.00 | 11.00 | 0.04M | 0.04M | 0.04M | -0.11M | 0.04M | 0.04M | 0.04M | -0.11M | 0.05M | 0.05M | 0.05M | ||||||||||||||||||
| Operating ExpensesOpex | 0.34M | 0.40M | 0.44M | 0.57M | 0.59M | 0.61M | 0.53M | 0.53M | 0.47M | 0.52M | 0.57M | 0.64M | 0.72M | 0.63M | 0.60M | 0.81M | 0.48M | 0.55M | 0.47M | 0.39M | |||||||||||||||||
| Operating IncomeOp. Inc | -0.34M | -0.40M | -0.44M | -0.57M | -0.59M | -0.61M | -0.53M | -0.53M | -0.47M | -0.52M | -0.57M | -0.64M | -0.72M | -0.63M | -0.60M | -0.81M | -0.48M | -0.55M | -0.47M | -0.39M | |||||||||||||||||
| EBIT | -0.34M | -0.40M | -0.44M | -0.57M | -0.59M | -0.61M | -0.53M | -0.53M | -0.47M | -0.52M | -0.57M | -0.64M | -0.72M | -0.63M | -0.60M | -0.81M | -0.48M | -0.55M | -0.47M | -0.39M | |||||||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.15M | 0.01M | 0.02M | ||||||||||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.01M | ||||||||||||||||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.11M | -0.06M | -0.21M | -0.09M | -0.64M | -0.07M | -0.13M | -0.19M | -0.39M | -0.82M | -0.15M | -0.26M | -0.46M | -0.13M | -0.26M | -0.39M | -0.04M | -0.12M | -0.98M | -0.19M | |||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||||||
| EBT | -0.45M | -0.46M | -0.65M | -0.67M | -1.23M | -0.68M | -0.67M | -0.73M | -0.86M | -1.34M | -0.72M | -0.91M | -1.18M | -0.76M | -0.86M | -1.20M | -0.52M | -0.67M | -1.45M | -0.58M | |||||||||||||||||
| Profit After TaxPAT | -0.45M | -0.46M | -0.65M | -0.67M | -1.23M | -0.68M | -0.67M | -0.73M | -0.86M | -1.34M | -0.72M | -0.91M | -1.18M | -0.76M | -0.86M | -1.20M | -0.52M | -0.67M | -1.45M | -0.58M | |||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -0.45M | -0.46M | -0.65M | -0.67M | -1.23M | -0.68M | -0.67M | -0.73M | -0.86M | -1.34M | -0.72M | -0.91M | -1.18M | -0.76M | -0.86M | -1.20M | -0.52M | -0.67M | -1.45M | -0.58M | |||||||||||||||||
| Income from Discontinued OperationsIncome (Discontinued) | |||||||||||||||||||||||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -0.45M | -0.46M | -0.65M | -0.67M | -1.23M | -0.68M | -0.67M | -0.73M | -0.86M | -1.34M | -0.72M | -0.91M | -1.18M | -0.76M | -0.86M | -1.20M | -0.52M | -0.67M | -1.45M | -0.58M | |||||||||||||||||
| Income towards Parent CompanyParent Net Inc | -0.45M | -0.46M | -0.65M | -0.67M | -1.23M | -0.68M | -0.67M | -0.73M | -0.86M | -1.34M | -0.72M | -0.91M | -1.18M | -0.76M | -0.86M | -1.20M | -0.52M | -0.67M | -1.45M | -0.58M | |||||||||||||||||
| Net Income towards Common StockholdersNet Income | -0.45M | -0.46M | -0.65M | -0.67M | -1.23M | -0.68M | -0.67M | -0.73M | -0.86M | -1.34M | -0.72M | -0.91M | -1.18M | -0.76M | -0.86M | -1.20M | -0.52M | -0.67M | -1.45M | -0.58M | |||||||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||||||
| EPS (Basic) | -0.06 | -0.01 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -1.07 | -0.62 | -0.70 | -0.94 | -0.39 | -0.42 | -0.90 | -0.36 | |||||||||||||||||
| EPS (Diluted) | -0.06 | -0.01 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -1.07 | -0.62 | -0.70 | -0.94 | -0.39 | -0.42 | -0.90 | -0.36 | |||||||||||||||||
| Shares Outstanding | 7.35M | 35.24M | 36.35M | 36.72M | 36.40M | 37.30M | 37.30M | 37.30M | 37.40M | 38.47M | 43.33M | 44.23M | 1.10M | 1.23M | 1.24M | 1.27M | 1.33M | 1.61M | 1.61M | 1.61M | |||||||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 7.35M | 35.24M | 36.35M | 36.72M | 36.40M | 37.30M | 37.30M | 37.30M | 37.40M | 38.47M | 43.33M | 44.23M | 1.10M | 1.23M | 1.24M | 1.27M | 1.33M | 1.61M | 1.61M | 1.61M | |||||||||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 7.35M | 35.25M | 36.62M | 36.73M | 37.30M | 37.30M | 37.30M | 37.30M | 38.26M | 42.80M | 44.23M | 44.24M | 1.29M | 1.22M | 1.26M | 1.42M | 1.33M | 1.61M | 1.61M | 1.61M | |||||||||||||||||
| EBITDA | -0.34M | -0.40M | -0.44M | -0.57M | -0.59M | -0.61M | -0.53M | -0.53M | -0.47M | -0.52M | -0.57M | -0.64M | -0.72M | -0.63M | -0.60M | -0.81M | -0.48M | -0.55M | -0.47M | -0.39M | |||||||||||||||||
| Interest ExpensesInt Expense | 0.15M | 0.01M | 0.02M |